Tofacitinib: A Janus Kinase Inhibitor for Rheumatoid Arthritis

Prescriber - United Kingdom
doi 10.1002/psb.1602
Full Text
Abstract

Available in full text

Categories
Pharmacology
Date
Authors
Publisher

Wiley

Related search

An Oral Spleen Tyrosine Kinase (Syk) Inhibitor for Rheumatoid Arthritis

New England Journal of Medicine
Medicine
2010English

Fournier's Gangrene That Initially Mimicked Pubic Cellulitis in an Elderly Woman Administered a Janus Kinase Inhibitor, Methotrexate, and Prednisolone for Rheumatoid Arthritis

Journal of Cutaneous Immunology and Allergy
2020English

SAT0177 Real-World Interruptions in Janus Kinase Inhibitor Therapy Observed Among Biologic-naÏve and Biologic-Experienced Rheumatoid Arthritis Patients

2018English

Experience With Tofacitinib in the Treatment of Resistant Rheumatoid Arthritis

Modern Rheumatology Journal
2015English

Pms51 - Cost-Effectiveness of Tofacitinib-Containing Sequences for Rheumatoid Arthritis Patients in Spain

Value in Health
MedicineHealth PolicyPublic HealthOccupational HealthEnvironmental
2018English

Elderly-Onset Varicella Pneumonia in a Patient With Rheumatoid Arthritis Taking Tofacitinib

Arthritis and Rheumatology
RheumatologyAllergyImmunology
2018English

P133 Clinical and Immunological Effects of Tofacitinib Therapy in Rheumatoid Arthritis

2019English

Effect of Janus Kinase Inhibition by Tofacitinib on Body Composition and Glucose Metabolism

Journal of Medical Investigation
BiochemistryMedicineGeneticsMolecular Biology
2018English

Comments on the Article “Effectiveness and Safety of Tofacitinib in Rheumatoid Arthritis: A Cohort Study”

Arthritis Research & Therapy
2018English

Amanote Research

Note-taking for researchers

Follow Amanote

© 2024 Amaplex Software S.P.R.L. All rights reserved.

Privacy PolicyRefund Policy